We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Fresenius SE and Company KGaA (PK) | USOTC:FSNUY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.112 | -1.48% | 7.4405 | 7.32 | 7.63 | 7.53 | 7.4405 | 7.53 | 44,836 | 21:23:30 |
By Ed Frankl
Fresenius SE said Tuesday that second-quarter profits fell, buffeted by "significantly worsening" business at its subsidiary Fresenius Medical Care AG and a challenging macroeconomic situation.
Last week, the German healthcare company cut its guidance for the year after its 32%-owned subsidiary FMC said it would lower its outlook due to U.S. labor shortages and a worsening economic environment.
Fresenius's net income in the three months to the end of June fell 5% to 450 million euros ($461.8 million), though its sales climbed 8% to EUR10.02 billion.
Dialysis-care company FMC said its net income fell almost 40% to EUR147 million, while revenue rose 10% to EUR4.76 billion.
Fresenius Kabi, a drug-making subsidiary, had solid organic sales growth, while its Helios private-hospital operator continued good admissions growth at its German and Spanish markets, Fresenius said.
The Bad Homburg-based company confirmed its lowered guidance issued on July 27 of sales growth in a low-to-mid single-digit percentage range at constant currency, anticipating more pronounced headwinds in 2022 from supply-chain disruptions and cost inflation, including energy prices.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
August 02, 2022 01:44 ET (05:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Fresenius SE and Company... (PK) Chart |
1 Month Fresenius SE and Company... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions